SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 94 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $413,000 | -57.6% | 429,013 | -47.6% | 0.00% | -100.0% |
Q1 2022 | $975,000 | +3.6% | 818,962 | +844.6% | 0.00% | 0.0% |
Q4 2020 | $941,000 | +51.5% | 86,700 | +48.7% | 0.00% | 0.0% |
Q2 2020 | $621,000 | -30.4% | 58,300 | -54.8% | 0.00% | 0.0% |
Q4 2019 | $892,000 | -70.0% | 129,085 | -55.0% | 0.00% | -66.7% |
Q3 2019 | $2,975,000 | +8.0% | 286,600 | -3.6% | 0.00% | +50.0% |
Q2 2019 | $2,754,000 | +36.7% | 297,400 | +34.9% | 0.00% | 0.0% |
Q1 2019 | $2,015,000 | +189.9% | 220,500 | +76.8% | 0.00% | +100.0% |
Q4 2018 | $695,000 | +106.2% | 124,700 | +340.6% | 0.00% | – |
Q3 2018 | $337,000 | -80.0% | 28,300 | -82.8% | 0.00% | -100.0% |
Q2 2018 | $1,684,000 | +58.4% | 164,900 | +128.4% | 0.00% | 0.0% |
Q3 2017 | $1,063,000 | +144.9% | 72,200 | +167.4% | 0.00% | 0.0% |
Q2 2017 | $434,000 | – | 27,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |